Drug intelligence / Profile preview

travirtide

Development stage: Preclinical
Lead developer: JPT Peptide Technologies
Modality: Peptides

Overview

**Travirtide** is a highly potent, synthetic transduction enhancer peptide designed to significantly improve viral gene transfer efficiency, particularly with retroviral vectors in T cells and other mammalian cells. It facilitates enhanced viral entry, supporting applications in CAR-T cell engineering, TCR-T therapies, and gene therapy research for cancer, infections, and non-Hodgkin lymphoma. Available in clinical-grade (>95% purity, HPLC/MS) and research-use-only formulations, it reduces manufacturing complexity and costs in advanced cellular therapies by enabling robust transduction at low multiplicities of infection.

Brand names: Travirtide
Other names: Travirtide (CGP)Travirtide (RUO)

Beyond the preview

Go deeper on travirtide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on travirtide.

Explore the full profile